Tadekinig alfa - AB2 Bio

Drug Profile

Tadekinig alfa - AB2 Bio

Alternative Names: IL-18BP - AB2 Bio; Recombinant human IL-18 binding protein - AB2 Bio

Latest Information Update: 26 Sep 2016

Price : $50

At a glance

  • Originator AB2 Bio
  • Class Anti-inflammatories
  • Mechanism of Action Interferon gamma inhibitors; Interleukin 1 inhibitors; Interleukin 18 inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Adult-onset Still's disease

Most Recent Events

  • 01 Jul 2016 AB2 Bio completes a phase II clinical trial in Adult-onset Still's disease (Treatment-experienced) in Switzerland, Germany and France (SC) (NCT02398435)
  • 01 Feb 2015 Phase-II clinical trials in Adult-onset Still's disease (Treatment-experienced) in Germany and Switzerland (SC) (NCT02398435; EudraCT2014-002500-24 )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top